Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorPunjab Institute of Cardology
About this trial
The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment.
The main questions it aims to answer are:
* Does triple therapy result in greater reduction in LDL-C compared to dual therapy? * What adverse effects occur in participants receiving triple therapy?
Researchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels.
Participants will:
* Receive either dual or triple lipid-lowering therapy for 3 months * Attend regular follow-up visits for clinical assessment and laboratory testing * Undergo lipid profile evaluation at baseline and at the end of the study
Eligibility criteria
Qualifiers
Must be older than 18 years, male or female.
Diagnosis of ACS (Acute Coronary Syndrome) is confirmed when hospitalized.
Eligible for high-intensity statin therapy (atorvastatin)
Patients can provide written informed consent.
Disqualifiers
Intolerance or hypersensitivity to study drugs.
Liver or ALT/AST greater than three times the upper normal.
Renal dysfunction: estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m².
Gout with frequent bouts or severe hyperuricemia.
Trial design
Treatments tested in this trial
- Atorvastatin 40 Mg Oral Tablet
- Ezetimibe 10 mg
- Bempedoic Acid 180 MG Oral Tablet
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov